The GI Company Reports Additional Phase II Clinical Data Of Intestinal Trefoil Factor (rhITF) Oral Spray For Oral Mucositis

At the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology’s 2008 International Symposium on Supportive Care in Cancer (MASCC / ISOO) held last week in Houston, Texas, The GI Company reported secondary endpoints relating to Oral Mucositis A

More: continued here

Filed under: GastroIntestinal / Gastroentorology on July 4th, 2008